Evidence map›Paper›PMID 39421449›Full record

ArticleFrontiers in oncology2024

Very early remission and increased apoptosis with the use of Pentoxifylline in children with acute lymphoblastic leukemia.

Violeta Salceda-Rivera, Pablo C Ortiz-Lazareno, Georgina Hernández-Flores, Jorge R Vazquez-Urrutia, Jesus Meza-Arroyo, Monzerrat Pardo-Zepeda, Hugo Romo-Rubio, Cesar Barba-Barba, Fernando Sánchez-Zubieta, Carlos Alfredo Barrón-Gallardo and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02451774 (SAFETY AND EFFICACY OF PENTOXIFYLLINE VERSUS PLACEBO ADMINISTERED AS APOPTOSIS INDUCTOR DURING REMISSION INDUCTION PHASE OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02451774 phase2 / phase3unknown statusnot on this map

Safety and efficacy of pentoxifylline versus placebo administered as apoptosis inductor during remission induction phase of pediatric patients with acute lymphoblastic leukemia

TypeinterventionalSponsorRamón Óscar González-Ramella, Ph.DRan2015 to 2020Enrolled44ConditionsAcute Lymphoblastic LeukemiaArmsPentoxifylline Plus Chemotherapy, Placebo Plus Chemotherapy
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Violeta Salceda-RiveraImmunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, JAL, Mexico.
Pablo C Ortiz-LazarenoImmunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, JAL, Mexico.
Georgina Hernández-FloresImmunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, JAL, Mexico.
Jorge R Vazquez-UrrutiaImmunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, JAL, Mexico.
Jesus Meza-ArroyoDoctoral Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, JAL, Mexico.
Monzerrat Pardo-ZepedaDoctoral Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, JAL, Mexico.
Hugo Romo-RubioDepartment of Pediatric Hemato-Oncology, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, JAL, Mexico.
Cesar Barba-BarbaDepartment of Pediatric Hemato-Oncology, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, JAL, Mexico.
Fernando Sánchez-ZubietaDepartment of Pediatric Hemato-Oncology, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, JAL, Mexico.
Carlos Alfredo Barrón-GallardoDepartamento Académico de Disciplinas Especializantes de Ciencias de la Salud, Universidad Autonoma de Guadalajara, Zapopan, JAL, Mexico.
Oscar Gonzalez-RamellaDoctoral Program in Biomedical Sciences, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, JAL, Mexico.
Alejandro Bravo-CuellarImmunology Division, Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara, JAL, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Despite the improvement in survival in acute lymphoblastic leukemia (ALL), there are still cases with evasion of chemotherapy-induced apoptosis. The IKK/NF-κB signaling pathway contributes to antiapoptotic gene expression. Pentoxifylline (PTX) inhibits IkB phosphorylation, blocking NF-κB and antiapoptotic activity. Methods: We conducted a randomized, double-blind clinical trial on pediatric ALL patients undergoing induction therapy, assigning them to PTX or placebo group. Bone marrow aspirates were obtained on days 1, 8, 15, and 22. Apoptosis was assessed using Annexin-V/propidium iodide. Results: Results indicated that the PTX group exhibited higher apoptosis on day-8 (41.3% vs. 19.4%, Conclusion: Our study demonstrates that PTX enhances apoptosis and reduces MRD in pediatric acute lymphoblastic leukemia patients. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT02451774.

Indexed as

ALLapoptosischildhoodclinical trialsearly remissionMRDPentoxifyllinetreatment response

Identifiers

PMID39421449
PMCPMC11484046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.